CSPC PHARMA (01093.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Dec29

Stone Pharmaceutical Group Secures Approval for Multiple Drug Trials in China

12:33

Jade Pharmaceutical's SYH2072 Receives Approval for Clinical Trials from NMPA

10:32

Sino-Pharm Group's Suglatiglutin Dapagliflozin Metformin ER Tablets Approved by National Medical Products Administration

10:27

Stone Pharmaceutical Group Approved to Conduct Clinical Trials for GLP-1/GIP Receptor Dual Agonist Peptide Injection

10:24

Dec25

Cai Dongchen Increases Holdings in Stone Pharmaceutical Group

09:40

Dec23

Stone Pharmaceutics Receives Clinical Trial Approval Notice for Daratumumab Injection

08:51

Schedules & Filings

Schedules

Filings

Nov20

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 7.234 B, Net Income 1.053 B, EPS 0.0921

Nov18

Distribution Plan(CST)

Cash dividend 0.14 HKD

Oct20

Distribution Plan(CST)

Cash dividend 0.14 HKD

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change